the high-throughput screening of libraries of large numbers of compounds (literally millions in some cases) produced by combinatorial-type methods was routinely carried out (often at considerable expense). The assumption was that a multitude of drug leads would emerge simply as a consequence of the sheer volume of molecules examined. The expected surge in productivity did not, however, materialise [6] . This disappointing degree of success was generally attributed to defects in the nature of the libraries employed [1, 6] . Typically such collections were comprised of molecules of broadly similar structures. A general consensus has emerged since the mid-1990s that library size is not everything; the structural diversity of the library plays a crucial role in determining success (in terms of the frequency at which biologically active compounds (hits) are identified) in any screening process [1, 2, 4, 6, 7] . Nature 'sees' molecules as threedimensional surfaces of chemical information [1, 4, 8, 9] . Thus the biological activity of any given small molecule is inherently dependant upon its 3D shape, which in turn is directly controlled by its molecular structure. Structurally diverse libraries should therefore contain compounds with a diverse range of shapes and therefore a broad range of biological activities, which are capable of providing hits against a wide variety of biological targets with increased frequency [1, 10] . The key element of libraries of large numbers of compounds based around single scaffolds [1, 11, 12] . In principle, the screening of collections with higher levels of scaffold diversity should provide hits against a broad range of biological targets with increased frequency and decreased cost [1, 10] . This includes so-called 'undruggable' targets and processes. It has been argued that one of the reasons why these are traditionally viewed to be intractable to small molecule modulation is because of deficiencies in existing compound collections. That is, the molecules comprising such collections seem to be well suited to modulating 'traditional' medicinal chemistry targets, but lack the necessary structural features required to modulate other processes [1, 10, 16] .
Therefore, in order to identify molecules capable of modulating these more challenging targets there is a clear need for new small molecule collections with increased levels of structural (scaffold) diversity that span regions of bioactive chemical space not accessed by traditional compound libraries [1] . When considering the generation of scaffold diversity, it is important to note that the known universe of organic chemistry is dominated by a remarkably small number of molecular scaffolds [18] .
For example, in a recent study of known cyclic molecules, 0.25% of the molecular scaffolds were found in 50% of known compounds [18] . That is, a large percentage of the compounds were represented by only a small percentage of scaffolds [13] .
As another illustration of this point, there are around 25,000 possible mono-and bicyclic heteroaromatic compounds, yet only ~ 1,700 have been synthesised and reported to date [19] .
Furthermore, there are many examples of molecular scaffolds with proven biological relevance that are under-represented in current small molecule collections. In the majority of such cases, this relative paucity of compounds can be attributed to synthetic intractability. Thus, there is a need for the development of new and efficient methods of broad utility for the synthesis of both 'atypical' and novel molecular scaffolds so that the biological usefulness of these structures can be investigated and exploited further [1] . The enrichment of screening libraries with molecules based on such frameworks will allow the sampling of previously untapped regions of chemical space [1] . Compounds in such areas may have exciting, novel biological properties, including the ability to modulate more challenging underexploited drug targets.
Diversity-oriented synthesis (DOS) is a synthetic approach that seeks to efficiently generate structurally diverse compound collections [1] . Schreiber and co-workers first described the concept of DOS in two seminal publications in 2000 [20, 21] .
These reports introduced the idea that the forward analysis of synthetic pathways could be used to devise strategies to convert small numbers of structurally simple building blocks into larger collections of structurally complex and diverse compounds that efficiently interrogate wide regions of chemical space simultaneously. Since these landmark works, the field of DOS has evolved rapidly. Alternative DOS planning strategies have been developed which are more "focused" in nature, seeking to efficiently explore areas of chemical space that are thought to have an enhanced probability of containing bioactive compounds molecular structure in this context is the molecular scaffold, that is the core rigidifying feature of the molecule. It is the molecular scaffold that has the most influence upon how a molecule displays chemical information in 3D space; indeed, the shapespace coverage of any compound set stems mainly from the nature and 3D geometries of the central scaffolds, with the peripheral substituents being of minor importance [1, 11, 12] .
Traditional combinatorial libraries typically possessed low levels of scaffold diversity, and thus a limited overall structural, and consequently functional, diversity [6] . This explains their poor performance in many biological screens, particularly those where the precise nature of the biological target was unknown or illdefined (e.g. phenotypic screening). A lack of scaffold diversity is still apparent in many of the synthetic screening sets employed in more recent years, despite a growing appreciation of the importance of this feature [13] . Indeed, deficiencies in current compound collections are evidenced by the continuing decline in drug discovery successes by pharmaceutical companies [1, 6] .
It can be argued that the lack of scaffold, and thus functional, There is a widespread consensus that increasing the scaffold diversity in a small molecule library is one of the most effective ways of increasing its overall shape and structural diversity [1, 9, 17] . Libraries which are small in size but which contain compounds based around multiple scaffolds are generally regarded to have better biorelevant diversity than Towards drugging the 'undruggable': enhancing the scaffold diversity of synthetic small molecule screening collections using diversity-oriented synthesis
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A synthetic strategy commonly employed in DOS is the socalled reagent-based branching approach [1, 3] . This involves the use of a common starting material and different reagents. A short series of divergent, complexity-generating reactions are carried out, leading to the formation of a structurally diverse collection of functionalized compounds based around a diverse range of molecular scaffolds [3] . Two examples from our group of DOS using a reagent-based approach are shown in Scheme 1.
A key strategic feature in both cases was the incorporation of a phase-tag in the starting materials, which greatly simplified purification during library synthesis. In the first example a structurally simple flourous-tagged diazaoacetate 1 was converted to a library of 223 structurally diverse compounds based around 30 different core molecular scaffolds [25] . At the time this represented the highest number of different molecular [1] (for example DOS inspired by natural product synthesis [22, 23] and DOS around privileged structures [24] ).
The Spring group has a strong interest in the development of innovative DOS strategies, with an emphasis placed upon the efficient incorporation of scaffold diversity. There are two related strands running through this work: (1) the DOS of scaffold, and therefore structurally, diverse compound collections and (2) the development of novel methodologies and strategies that allow for the efficient synthesis of under-explored and novel molecular scaffolds, and the application of these methodologies in a DOS context. In this minireview some selected representative examples of work taken from the author's laboratories in both of these branches of research are described, with a particular focus upon new methods and strategies for the synthesis of unusual molecular scaffolds.
Scheme 1. Two examples of DOS using a reagent-based branching synthetic strategy. A) DOS from a fluorous tagged diazoacetate [25]; B) DOS using
a solid-supported phosphonate [26] . We have also developed another DOS strategy for generating macrocyclic scaffolds, more specifically a subset of macrocyles termed macrocyclic peptidomimetics [35] . Towards drugging the 'undruggable': enhancing the scaffold diversity of synthetic small molecule screening collections using diversity-oriented synthesis proteolysis and poor bioavailability) [36] . Numerous biologically active molecules contain cyclic peptide and peptidomimetic structural units including diketopiperazines (DKPs, the smallest possible cyclic peptides) and many compounds incorporating macrocyclic peptides and peptidomimetics are also known to be capable of modulating biological systems [29, 35, [37] [38] [39] [40] [41] .
Despite such valuable properties, macrocyclic peptides (as with macrocyclic compounds in general) are generally viewed as a poorly explored structural class within drug discovery [29, 35] . We have described a strategy for the DOS of a library of structurally unique and diverse macrocyclic peptidomimetics based around two general structural types (A and B, Scheme 3) from simple, readily available amino acid starting materials [35] . Each structural type contains a triazole ring in place of an amide bond, and structure B also incorporates a DKP in the macrocycle. Our strategy for the synthesis was based around a so-called build/couple/pair three-phase approach described by Nielsen and Schreiber [42] . In our case the build step involves the preparation of two types of chiral building blocks: (1) 'azidoamine' building blocks 11 which contain a free amine and an azide and (2) 'alkyne-acid' building blocks 12 which contain a carboxylic acid and an alkyne. Coupling of three of these also has an interest in devising efficient routes to more unusual (including novel) complex molecular scaffolds whose biological properties have yet to be explored or exploited.
Towards this end we have recently developed a folding-type process for the generation of skeletally diverse small molecules [47] . Substituted norbornene derivatives 26 were used in a tandem domino enyne metathesis-Diels Alder sequence that allows the generation of complex polycyclic scaffolds 27 in a highly efficient and atom-economical manner (Scheme 5) [43] . 
